首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 218 毫秒
1.
了9筛选适合于高原部队防治由于HP感染所致的上消化道疾痛的HP根除治疗方案,设计了5种不同的治疗方案,并对胃镜检查证实的140名HP阳性的患进行随机分组治疗,治疗结束后4周采用“C-尿素呼吸试验复查,溃痔患胃镜复查并行HP快速尿素醇试验和病理检查.结果表明:以蒋诺为主的2号和3号四联方案HP根除率分别为92.23%和91.67%,但不良反应较多;4号方案(雷尼替丁150mg2/天,甲硝唑200mg4/天,呋哺唑酮100mg4/天)HP根除率为83.33%,但与2号和3号四联方案比较并无显差异(P>0.05),且不良反应少,般从性好,药品成本低。因此,根据我们的结果,4号方案是一种较为理想的并适合于高原基层部队的HP根除治疗方案,值得在临床推广应用。  相似文献   

2.
我们对51例确诊幽门螺杆菌(HP)感染的活动性十二指肠溃疡患者给予雷尼替丁150mg,每日2次,共28天,羟氨苄青霉素500mg,每日3次,及甲硝唑400mg,每日2次,共14天治疗,于第6周复查胃镜、活检组织学、尿素酶试验和~(13)C 尿素呼吸试验,以鉴定溃疡愈合和 HP 根除情况。结果:HP 根除率88.2%,溃疡愈合率88.2%,副反应很小,显示本疗法是值得推荐的方案。  相似文献   

3.
目的比较序贯疗法与传统四联疗法对幽门螺杆菌(H.pylori)根除失败后补救治疗的临床疗效。方法选取胃镜下H.pylori快速尿素酶试验或14C尿素呼气试验阳性的患者,经我国标准H.pylori一线三联根除方案治疗7天,停药4周后检测H.pylori,结果仍为阳性者判定为H.pylori根治失败,即进行H.pylori的补救根除治疗,共68例患者入选。随机分为两组:治疗组予以序贯疗法:前5天口服埃索美拉唑20mg和阿莫西林1000mg,2次/d,后5天口服埃索美拉唑20mg、克拉霉素500mg和甲硝唑400mg,2次/d;对照组予以传统四联疗法:口服埃索美拉唑20mg、阿莫西林1000mg、呋喃唑酮100mg和胶体果胶铋100mg,2次/d,疗程7天。疗程结束后4周行14C尿素呼气试验检测H.pylori。结果疗程结束后4周,治疗组H.pylori根除率为93.9%,对照组H.pylori根除率为73.3%,两组H.pylori根除率比较有显著性差异(P0.05)。结论序贯疗法对H.pylori的根除率高于传统四联疗法,可作为有效的H.pylori补救根除治疗方案。  相似文献   

4.
目的:观察艾普拉唑或埃索美拉唑联合铋剂10天四联方案治疗幽门螺杆菌( HP)感染慢性胃炎的效果。方法120例经胃镜、快速尿素酶素实验确诊的HP感染慢性胃炎初治患者,按就诊顺序随机分为A、B组,各60例,分别接受埃索美拉唑或艾普拉唑+枸橼酸铋钾+阿莫西林克拉维酸钾+左氧氟沙星的10天四联疗法。疗程结束后4~6周行14 C尿素呼气实验检测HP根除情况,并观察临床症状改善及不良反应发生情况。结果 A组58例、B组52例共110例完成随访。 A、B组HP根除率差异症状缓解总有效率和不良反应发生率比较均无统计学差异。结论埃索美拉唑或艾普拉唑联合铋剂10天四联方案治疗HP感染慢性胃炎患者效果确切,且较为安全。  相似文献   

5.
目的:观察对比序贯疗法及含左氧氟沙星的四联疗法对首次根除幽门螺杆菌(Helicobacter pylori,H.pylori)失败患者行补救根除时的疗效.方法:自2010-09/2014-05共收集首次根除失败的H.pylori感染患者167例.随机分为2组,序贯治疗组共85例,四联治疗组82例.序贯治疗方法为:前5天予以雷贝拉唑10 mg,2次/d;阿莫西林胶囊1000 mg,2次/d;后5天予以雷贝拉唑10 mg,口服2次/d;克拉霉素分散片500 mg,2次/d;奥硝唑片0.5 g,2次/d.四联治疗方法为:雷贝拉唑10 mg,2次/d;枸橼酸铋钾胶囊300 mg2次/d;左氧氟沙星片0.2 g,2次/d;阿莫西林1000 mg,2次/d.四联药物共服药12 d.观察患者在治疗期间的药物不良反应.结果:治疗结束后1 mo复查14C呼气试验,共有152例患者随访成功.序贯治疗组有77例随访成功,60例为阴性,符合方案集(per-protocol P P)分析根除率为77.92%,意向性治疗原则(intention-to-treat,ITT)分析根除率为70.6%四联治疗组随访成功的75例,有3例发生严重不良反应而退出试验.72中有61例为阴性,PP分析根除率为84.72%,ITT分析根除率为74.4%.两组PP分析根除率及ITT根除率均无统计学差异(60/77与61/72,χ2=1.127,P=0.288;60/85与61/82,χ2=0.302,P=0.582).序贯治疗组随访的77例共有9例出现不良反应不良反应发生率为11.7%.四联治疗组随访的75例中,有11例发生不良反应,不良反应发生率分别为14.7%.两组不良反应发生率差异无统计学意义(χ2=0.295,P=0.587).结论:四联疗法及序贯疗法在对于首次H.pylori根除失败后再根除时的疗效无显著性差异.不推荐将两种疗法作为H.pylori的补救根治首选方案.  相似文献   

6.
目的探讨埃索美拉唑、阿莫西林和呋喃唑酮1周三联疗法根除幽门螺杆菌的疗效与安全性。方法将98例经^14C尿素酶呼气试验(^14C—UBT)和胃镜检查快速尿素酶试验均为阳性的初次根除幽门螺杆菌的患者随机分为A组和B组,均给予埃索美拉唑20mg,2次/天,加两种抗生素治疗1周,A组为呋喃唑酮100mg,2次/天加阿莫西林1000mg,2次/天;B组为克拉霉素500mg,2次/天加阿莫西林1000mg,2次/天,口服,治疗1周后停药,4周后复查^14C尿素酶呼气试验,并观察治疗期间不良反应率。结果A组Hp根除率为94.2%,B组为82.6%,两组根除率比较差异有显著性(P〈0.05),两组间不良反应发生率比较无显著性差异(P〉0.05)。结论由埃索美拉唑、呋喃唑酮和阿莫西林组成的1周三联疗法可获得更高的Hp根除率,且安全性好,是较理想的Hp根除方案。  相似文献   

7.
目的 探讨含左氧氟沙星的四联补救方案抗幽门螺杆菌(HP)治疗的疗效和药物副作用.方法 将HP感染经常规三联疗法(奥美拉唑 阿莫西林 克拉毒素)治疗失败的84例患者分为A组(44例)和B组(40例).A组患者给予以左旋氧氟沙星为主的四联补救治疗7天(左氧氟沙星 奥美拉唑肠溶片 阿莫西林 胶体果胶铋),B组患者使用常规四联7天(洛赛克 胶体果胶铋 克拉毒素 甲硝唑)补救疗法,4周后做13c尿素酶呼吸试验,并作比较.结果 A组3例失访,余41例完成治疗及随访,其中36例(89.7%)补救根除成功,5例(11.3%)补救治疗失败,7例(17.1%)患者发生轻微不良反应;B组4例失访,25例(69.3%)根除成功,8例(22.2%)患者发生轻微不良反应,A、B两组Hp根除率比较有显著性差异(P<0.05).结论 含左氧氟沙星的四联方案为安全有效的幽门螺杆菌补救治疗方案.  相似文献   

8.
我们对51例确诊幽门螺杆菌(HP)感染的活动性十二指肠溃疡患给予雷尼替丁150 mg,每日2次.共28天.羟氨苄青霉隶500mg,每日3次,及甲硝唑400mg,每日2次,共14天治疗.于第6周复查胃镜、活检组织学、尿素酶试验和^13 C尿素呼吸试验.以鉴定溃疡愈合和HP根除情况。结果:HP根除率88.2%,溃疡愈合率88.2%.副反应很小,显示本疗法是值得推荐的方案.  相似文献   

9.
目的探讨标准三联及经典四联方案联合铝碳酸镁根除幽门螺杆菌(Helicobacter pylori,H.pylori)的疗效。方法纳入2015年6月陆军某部男性官兵~(13)C-尿素呼气试验阳性者384例,按区组随机化法分为4组,每组96例。A组用标准三联方案(雷贝拉唑肠溶片20 mg+阿莫西林1 000 mg+克拉霉素500 mg);B组用含铝碳酸镁四联方案(A组基础上+铝碳酸镁1 000 mg),C组用含铋剂经典四联方案(A组基础上+胶体果胶铋400 mg),D组用含铝碳酸镁及铋剂的五联方案(C组基础上+铝碳酸镁1 000 mg),疗程均为10 d。治疗结束停药后4周复查~(13)C-尿素呼气试验,并随访3个月,评估患者依从性、H.pylori根除率、消化道症状缓解情况和不良反应。结果 97.1%患者按方案完成治疗,各组完成率差异无统计学意义(P0.05)。A、B、C、D组按意向性分析(ITT)根除率分别为79.2%、91.7%、90.6%和94.8%,按方案集分析(PP)根除率分别为82.6%、92.6%、94.6%和96.8%,B、C、D组ITT根除率及PP根除率均高于A组(P0.05)。各组消化道症状均有缓解,缓解率由高到低依次为D、B、C、A组,仅D组腹痛和反酸嗳气缓解率高于A组,差异有统计学意义(P0.05)。A、B、C、D组不良反应发生率分别为79.2%、20.8%、83.3%、46.9%,B组不良反应发生率低于其他三组(P0.05),D组不良反应发生率低于A组和C组(P0.05)。结论含铝碳酸镁四联方案与含铋剂四联方案根除H.pylori的疗效相当,且均高于标准三联方案,而含铝碳酸镁四联方案组不良反应发生率低于其他三组。H.pylori根除后含铝碳酸镁及铋剂的五联方案组腹痛和反酸嗳气缓解率高于标准三联方案组。  相似文献   

10.
[目的]观察含呋喃唑酮的四联疗法治疗幽门螺旋杆菌(Hp)初次根除失败的疗效和不良反应。[方法]选择消化性溃疡和慢性胃炎Hp感染者进行过1次Hp根除治疗,且治疗结束后抗生素停用至少4周、PPI停用至少2周,复查Hp仍为阳性者共90例。治疗组口服雷贝拉唑、枸橼酸铋钾、阿莫西林、呋喃唑酮治疗;对照组口服雷贝拉唑、枸橼酸铋钾颗粒、阿莫西林、左氧氟沙星;2组疗程均为14 d。停药4周,复查~(14)C尿素呼气试验,观察Hp的根除率和不良反应。[结果]治疗组的Hp根除率意向性分析(ITT)、方案分析(PP)分別为87.5%、91.3%,对照组分别为71.4%、73.2%,2组比较均差异有统计学意义(P0.05);治疗组、对照组不良反应率为10.4%∶9.5%,差异无统计学意义(P0.05)。[结论]含呋喃唑酮的四联疗法治疗Hp初次根除失败者根除率较高,不良反应少,值得本地区推广使用。  相似文献   

11.
Background: A proton pump inhibitor (PPI)‐based triple therapy with clarithromycin (CAM) and amoxicillin (AMPC) is now a standard regimen for Helicobacter pylori (HP) eradication in Japan. However, the CAM‐resistant rate has increased recently and alternative therapies are sorely needed. Therefore the aim of the present study was to evaluate the effectiveness and safety of the PPI–tetracycline (TC)–metronidazole (MNZ) regimen (the PTM regimen) as an alternative therapy in comparison with the PPI–AMPC–MNZ (PAM) regimen. Methods: Sixty‐four HP‐positive patients visiting the HP‐eradication clinic in Tokai University Hospital from July 1998 to March 2003 were treated with either PTM or PAM as alternative therapies. The HP eradication was assessed by urea breath test (UBT), HP stool antigen test, or HP culture method more than 2 months after completion of the treatments. The drug resistances against CAM, AMPC, TC, and MNZ were assessed by the agar dilution method. Results: Fifty‐six patients (26 PTM and 30 PAM) completed medication and evaluation of the eradication. The eradication rates of PTM were 82.8% (24/29) and 92.3% (24/26), while those of PAM were 74.3% (26/35) and 89.7% (26/29) by intention‐to‐treat and per‐protocol analysis, respectively. The differences between the regimens were not statistically significant. There were no severe adverse effects observed in either of the regimens. The drug‐resistance analyses showed 15 CAM‐ and one MNZ‐resistant cases but no TC or AMPC resistance in the available 25 samples. Conclusion: The PTM and PAM regimens were equally effective and safe as alternative HP eradication therapies. And PTM would be particularly useful in penicillin allergy cases.  相似文献   

12.
目的观察不同疗程奥美拉唑三联方案根除幽门螺杆菌(Hp)后的复发率。方法Hp阳性的干二指肠溃疡103例患者,随机分为二组:A组50例;B组53例。均给予奥美拉唑20 mg(每日2次)、阿莫西林1.0 g(每日2次)、呋喃唑酮0.1 g(每日3次),A组疗程2周,B组疗程1周。观察2组Hp根除率、溃疡复发率、3年Hp复发率及不良反应。结果A组Hp根除率、溃疡愈合率、Hp根除者3年累积复发率分别为92.0%、96.0%、8.7%;B组分别为88.7%、92.5%、12.8%,两组三项差异均无显著性(P>0.05)。结论1周和2周疗程方案近、远期疗效相同,但1周疗程方案疗程短,病人依从性好,费用减半,效-价比优于2 周疗程方案。  相似文献   

13.
目的探索根除率较高、价廉、安全实用的HP根除方案.方法137例消化性溃疡或糜烂性胃窦炎患者,随机分为3组A组44例,以奥美拉唑20mg+克拉霉素250mg+替硝唑500mg每天2次,疗程7天,即Bazzoli方案;B组47例,以奥美拉唑20mg+阿莫西林1000mg+呋喃唑酮100mg,每天2次,疗程7天;C组46例,以兰索拉唑30mg每天1次,阿莫西林1000mg+呋喃唑酮100mg每天2次,疗程7天.活动期溃疡患者抗HP治疗后继服奥美拉唑20mg或兰索拉唑30mg,每天1次,3周.抗HP治疗结束1月后复查胃镜并检测HP.结果A、B、C3组的HP根除率分别为90.9%、87.2%和89.1%;活动期溃疡愈合率分别为100%、93.8%和100%;糜烂性胃窦炎愈合率分别为85.2%、79.2%和92.2%;副反应发生率分别为13.6%、6.4%和8.7%.各组间差异无显著性,P>0.05.A、B、C3组每例抗HP所需费用分别为544.5元、309.0元和170.5元.结论方案B、C是2种新的、根除率较高、价廉、安全实用的HP根除方案.  相似文献   

14.
Objectives: Our objectives were to determine the effect of dual therapy with omeprazole and amoxicillin and of triple therapy with omeprazole, amoxicillin, and metronidazole in the eradication of Helicobacter pylori (HP) and to study the long-term results of eradication in these patients. Methods: A prospective, randomized, controlled trial was performed. Patients who were recruited had unequivocal evidence of HP infection based on culture, histology, rapid urease test, and Gram's stain of a tissue smear. Eradication was defined as the absence of bacteria in all tests performed on both corpus and antral biopsies. Results: The infection was eradicated in 15 of 19 (78.9%) patients randomized to receive dual therapy and in 19 of 22 (86.4%) patients who received triple therapy. We followed the course of 30 patients in whom HP had been eradicated for a prolonged term (up to 12 months). All remained clear of HP. Twenty-five of 28 patients (89.3%) with duodenal ulcers in whom HP was successfully eradicated remained healed at 12 months. Fewer side effects were reported among patients who received the dual therapy. Conclusions: Combination therapy with omeprazole and amoxicillin with or without metronidazole is effective in the eradication of HP. In particular, the dual therapy regimen with amoxicillin is not only effective but is also well tolerated by patients.  相似文献   

15.
根除幽门螺杆菌三联疗法临床观察   总被引:2,自引:0,他引:2  
目的 观察以质子泵抑制剂 (PPI)、克拉霉素为中心的三联疗法治疗幽门螺杆菌 (HP)阳性十二指肠溃疡的疗效 ,比较甲硝唑和痢特灵的疗效及副作用 ,筛选理想的三联疗法。方法 胃镜确诊十二指肠溃疡并经病理组织学及 14 C-尿素呼吸试验证实 HP感染者 184例 ,随机分成 2组 ,A组用洛塞克、克拉霉素及甲硝唑 ,B组用洛塞克、克拉霉素及痢特灵 ,每日 2次 ,连续 7d,停药 4周后复查胃镜观察溃疡愈合程度 ,同时经 14 C-尿素呼吸试验及胃镜证实 HP根除情况。结果 溃疡总愈合率 :A组 91.4 % (85 / 93) ,B组 93.4 % (85 / 91) ,2种疗法比较差异无显著意义 (P >0 .0 5 ) ;HP根除率 :A组 90 .3% (84 / 93) ,B组 93.4 % (85 / 91) ,2种疗法比较差异无显著意义 (P >0 .0 5 ) ;轻度不良反应 :A组 16 .1% (15 / 93) ,B组 4 .4 % (4/ 91) ,B组反应明显轻于 A组 (P <0 .0 5 )。结论  2组三联疗法根除 HP及治疗十二指肠溃疡均有良好疗效 ;痢特灵具有抗 HP作用强、无耐药性、价格低廉、副作用少等优点 ,可替代甲硝唑配伍于洛塞克、克拉霉素的三联疗法中 ,是一种理想的适合国情的根除 HP方案  相似文献   

16.
BACKGROUND: Several studies have found a fairly low Helicobacter pylori eradication rate using a standard 7-day triple therapy in Italy. Recently, two new therapeutic schedules have been proposed with an eradication rate higher than 90%. This study compared the efficacy of these two treatment regimens. PATIENTS AND METHODS: A total of 131 patients with Helicobacter pylori infection and either non-ulcer dyspepsia (73 patients] or peptic ulcer (58 patients) were enrolled. Helicobacter pylori infection was assessed by rapid urease test and histology on gastric biopsies. Patients were randomised to receive either a 5-day course of ranitidine bismuth citrate 400 mg bid, clarithromycin 500 bid, and tinidazole 500 bid, or a 10-day course of omeprazole 20 mg bid plus amoxycillin 1 g bid for the first 5 days, and omeprazole 20 mg bid, clarithromycin 500 mg bid and tinidazole 500 mg bid for the remaining 5 days. Eradication was assessed by endoscopy 4-6 weeks after therapy. RESULTS: Overall, 4 patients (2 for each treatment group) were lost to follow-up. Helicobacter pylori eradication rates were 67.2% (95% confidence interval: 55.7-78.7) and 65.2% (95% confidence interval: 53.7-76.6) at per protocol and intention-to-treat analyses, respectively, after the 5-day regimen, and 96.8% (95% confidence interval: 92.5-100) and 93.8% (95% confidence interval: 88-99.7) after the 10-day regimen (p<0.05). Both treatments were well tolerated, and no major side-effects were reported. CONCLUSIONS: The 5-day regimen gave disappointing results, while the eradication rate after the 10-day regimen was very high.  相似文献   

17.
背景:随着幽门螺杆菌(Hp)耐药率的上升及其所导致的标准三联疗法根除率的下降,铋剂四联方案成为我国最新共识推荐的Hp感染根除治疗方案。目的:评价各共识推荐铋剂四联方案的根除治疗效果,为高效、价廉的根除治疗方案的选择提供参考。方法:检索CNKI、万方、维普数据库,纳入我国2011-2013年间公开发表,采用共识推荐的铋剂四联方案根除Hp感染的临床试验类文献。提取文献资料,根据Graham等提出的Hp根除率分级系统,对根除率进行分析。结果:共166篇文献入选,包括Hp感染根除试验192项。在全国范围内,含阿莫西林方案的根除率大部分可以接受,其中PAFB(PPI+阿莫西林+呋喃唑酮+铋剂)方案取得优异根除率(≥95%)的可能性最高。在华东和中南地区,相应的适宜根除治疗方案分别为PACB(PPI+阿莫西林+克拉霉素+铋剂)和PAFB方案。适宜疗程为14 d。结论:在各共识推荐铋剂四联方案中,PAFB方案具有明显的效益和成本优势。在全国范围内,非阿莫西林过敏个体行Hp感染根除治疗宜优先选用PAFB方案,建议疗程为14 d。  相似文献   

18.
BACKGROUND/AIMS: To evaluate whether omeprazole, amoxicillin and clarithromycin for 12 days is more effective for Helicobacter pylori eradication than the same regimen for only 6 days; and to verify whether these eradication regimens are more effective in peptic ulcer disease than in non-ulcer dyspepsia. METHODOLOGY: We studied 411 patients in whom a gastroscopy was carried out due to symptoms related to the upper gastrointestinal tract and who were diagnosed with duodenal ulcer (175 patients, 43%), gastric ulcer (42 patients, 10%), or non-ulcer dyspepsia (194 patients, 47%), and concomitant infection by H. pylori. At endoscopy, biopsies were obtained for rapid urease test, and a 13C-urea breath test was carried out. Urea breath test was repeated four weeks after completing eradication treatment with 1) omeprazole (20 mg b.i.d.), amoxicillin (1 g b.i.d.) and clarithromycin (500 mg b.i.d.) for six days (239 patients), or 2) the same regimen for 12 days (172 patients). RESULTS: H. pylori eradication was achieved in 73.6% (95% CI, 68-79%) of the patients treated during 6 days, and in 84.3% (79-90%) of those receiving 12 days of therapy (P < 0.01). The overall eradication rate with both regimens (6 plus 12 days), respectively in patients with duodenal ulcer, gastric ulcer and non-ulcer dyspepsia, was 84.6% (79-90%), 75.6% (61-86%), and 72.8% (67-79%) (P < 0.01 when comparing duodenal ulcer vs. non-ulcer dyspepsia). Twelve-day regimen was more effective than 6-day regimen only in non-ulcer dyspepsia (62% vs. 83%, P < 0.01), but not in duodenal or gastric ulcer. In the multivariate analysis the duration (6 vs. 12 days) of eradication therapy (odds ratio: 2.2; 1.3-3.7) and the type of disease (duodenal ulcer vs. non-ulcer dyspepsia; odds ratio: 2.3; 1.3-3.8) were the only variables which influenced on H. pylori eradication efficacy (chi 2 model, 17; P < 0.001). CONCLUSIONS: Efficacy with omeprazole-amoxicillin-clarithromycin regimen in patients with duodenal ulcer is higher than in those patients with non-ulcer dyspepsia. The increase of H. pylori eradication rate by 21% in our non-ulcer dyspepsia patients justifies the prolongation from 6 to 12 days of omeprazole-amoxicillin-clarithromycin therapy, whilst the increase of cure rates in duodenal or gastric ulcer patients with a 12-day therapy would not be cost-effective.  相似文献   

19.
Background: Patients with insulin-dependent diabetes mellitus (IDDM) are often affected by chronic infections; antibiotic absorption, however, may be influenced by the disease. H. pylori eradication appears to be reduced in IDDM patients. The aim of the study was to evaluate the efficacy of the most common H. pylori eradication regimens in a population of IDDM-infected patients. Methods: One hundred and seventy-two IDDM patients were evaluated. H. pylori infection was assessed through the 13C-urea breath test. Infected patients were randomly assigned to three different standard 7-day eradication regimens: 1) amoxicillin, clarithromycin, pantoprazole; 2) tinidazole, clarithromycin, ranitidine bismuth citrate; or 3) tinidazole, clarithromycin, pantoprazole. Patients in whom eradication was not successful in the first cycle were subsequently submitted to a 7-day therapy with tinidazole, tetracycline, bismuth, and pantoprazole. Results: Thirty-seven per cent of IDDM patients were infected. None of the triple therapies used provided an eradication higher than 62%. Conversely, the quadruple regimen was successful in 88% of the patients. Ten per cent of the subjects undergoing the triple therapies showed minor side effects, without significant differences among groups, whereas side effects occurred in 25% of the patients treated with the quadruple therapy (P &lt; 0.05). Conclusions: IDDM patients show a low H. pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently. The use of a quadruple regimen leads to the cure of a large percentage of the infected patients in whom the eradication was unsuccessful in the first therapy, although it is accompanied by a greater incidence of minor side effects.  相似文献   

20.
BACKGROUND: Patients with insulin-dependent diabetes mellitus (IDDM) are often affected by chronic infections; antibiotic absorption, however, may be influenced by the disease. H. pylori eradication appears to be reduced in IDDM patients. The aim of the study was to evaluate the efficacy of the most common H. pylori eradication regimens in a population of IDDM-infected patients. METHODS: One hundred and seventy-two IDDM patients were evaluated. H. pylori infection was assessed through the 13C-urea breath test. Infected patients were randomly assigned to three different standard 7-day eradication regimens: 1) amoxicillin, clarithromycin, pantoprazole; 2) tinidazole, clarithromycin, ranitidine bismuth citrate; or 3) tinidazole, clarithromycin, pantoprazole. Patients in whom eradication was not successful in the first cycle were subsequently submitted to a 7-day therapy with tinidazole, tetracycline, bismuth, and pantoprazole. RESULTS: Thirty-seven per cent of IDDM patients were infected. None of the triple therapies used provided an eradication higher than 62%. Conversely, the quadruple regimen was successful in 88% of the patients. Ten per cent of the subjects undergoing the triple therapies showed minor side effects, without significant differences among groups, whereas side effects occurred in 25% of the patients treated with the quadruple therapy (P < 0.05). CONCLUSIONS: IDDM patients show a low H. pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently. The use of a quadruple regimen leads to the cure of a large percentage of the infected patients in whom the eradication was unsuccessful in the first therapy, although it is accompanied by a greater incidence of minor side effects.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号